P2371
Pamidronate disodium salt hydrate
≥95% (NMR), Bone resorption inhibitor, solid
Synonym(s):
3-Amino-1-hydroxy-1-phosphonopropanephosphonic acid disodium salt hydrate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C3H9NO7P2Na2 · xH2O
CAS Number:
Molecular Weight:
279.03 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
260-647-1
MDL number:
Product Name
Pamidronate disodium salt hydrate, ≥95% (NMR), solid
Quality Level
assay
≥95% (NMR)
form
solid
color
white
mp
300 °C
solubility
H2O: 28 mg/mL
originator
Novartis
storage temp.
2-8°C
SMILES string
O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O
InChI
1S/C3H11NO7P2.2Na.H2O/c4-2-1-3(5,12(6,7)8)13(9,10)11;;;/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11);;;1H2/q;2*+1;/p-2
InChI key
TVQNUQCYOOJTMK-UHFFFAOYSA-L
Biochem/physiol Actions
Bone resorption inhibitor; inhibitor of farnesyl diphosphate synthase (IC50 = 200 nM).
Pamidronate disodium has the ability to block Wnt and β-catenin signaling, which modulates the osteogenic differentiation in bone marrow mesenchymal stem cells (BMMSCs). It can also reduce bilirubin-impaired apoptosis and helps to develop dentinogenic dysfunction of stem cells from human deciduous teeth.
Features and Benefits
This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ratna Chatterjee et al.
British journal of haematology, 159(4), 462-471 (2012-09-13)
This study aimed to evaluate bone remodelling disorders in thalassaemia by using pamidronate (PD) infusion with or without hormone replacement therapy (HRT) as a diagnostic-therapeutic tool. In this prospective study, 24 adult thalassaemia major (TM) and 10 thalassaemia intermedia (TI)
Marcin Kos et al.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 71(6), 1010-1016 (2013-03-16)
Bacterial colonization of the denuded bone in bisphosphonate-related osteonecrosis of the jaw suggests that bisphosphonates increase bacterial adhesion and biofilm formation. This study evaluated the adhesion of gram-positive and gram-negative bacteria on hydroxyapatite coated with pamidronate, one of the most
Uncomplicated vaginal delivery in two consecutive pregnancies carried to term in a woman with osteogenesis imperfecta type I and bisphosphonate treatment before conception.
Chih-Ping Chen et al.
Taiwanese journal of obstetrics & gynecology, 51(2), 305-307 (2012-07-17)